Cargando…
A Selective PPARγ Modulator Reduces Hepatic Fibrosis
Hepatic fibrosis is the accumulation of excess collagen as a result of chronic liver injury. If left unabated, hepatic fibrosis can lead to the disruption of the liver architecture, portal hypertension, and increased risk of progression to cirrhosis and hepatocellular carcinoma. The thiazolidinedion...
Autores principales: | McVicker, Benita L., Hamel, Frederick G., Simpson, Ronda L., Bennett, Robert G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407562/ https://www.ncbi.nlm.nih.gov/pubmed/32630819 http://dx.doi.org/10.3390/biology9070151 |
Ejemplares similares
-
Reduction in Obesity-Related Hepatic Fibrosis by SR1664
por: McVicker, Benita L., et al.
Publicado: (2023) -
Serelaxin increases the antifibrotic action of rosiglitazone in a model of hepatic fibrosis
por: Bennett, Robert G, et al.
Publicado: (2017) -
Novel Anti-fibrotic Therapies
por: McVicker, Benita L., et al.
Publicado: (2017) -
Alcohol-induced tubulin post-translational modifications directly alter hepatic protein trafficking
por: Adhikari, Raghabendra, et al.
Publicado: (2023) -
p38γ Activation and BGP (Biliary Glycoprotein) Induction in Primates at Risk for Inflammatory Bowel Disease and Colorectal Cancer—A Comparative Study with Humans
por: Talwar, Harvinder, et al.
Publicado: (2020)